Reviewed August 2026 by the Corydalis Labs Technical Team. How we research and review.
The shape of it
If you have been in this category since 2023 you have lived through the same cycle three times. A compound arrives that lets brands differentiate. It scales. It attracts attention. It comes under regulatory action. Everyone scrambles for the next one, and the next one buys less time than the last.
That is not a run of bad luck. It is a mechanism, and once you can see it you can predict roughly what happens to any candidate ingredient before you commit a production run to it.
What happened to what
| Compound | What happened | Where it stands |
|---|---|---|
| 7-OH 7-hydroxymitragynine | Scaled rapidly in concentrated products. FDA issued warning letters to firms marketing it, citing claims about pain, withdrawal, and dependence. Several states scheduled it through emergency rulemaking. DEA filed notices of intent to temporarily schedule in July 2026. | Under federal action |
| Mitragynine pseudoindoxyl | Adopted widely as a 7-OH replacement. Named in the same July 2026 notices, and in several state actions before that. | Under federal action |
| MGM-15 and MGM-16 MGM-15 also sold as Oxonol | Marketed as a next-generation option. Named in the same July 2026 notices. | Under federal action |
| Mitragynine | Not federally scheduled. Increasingly regulated at state level through kratom consumer protection statutes — age restriction, labelling, permitting — with outright prohibition in six states. | Regulated, sellable |
Why each replacement bought less time
Look at the source of each compound in that table. 7-OH is a derivative of mitragynine. Pseudoindoxyl is a rearrangement product of mitragynine. MGM-15 and MGM-16 are semi-synthetics built on the same chemistry.
Once regulators are examining a chemical family, derivatives of that family inherit the attention. That is not an accident of enforcement priorities — it is deliberately built into how the Controlled Substances Act works. Schedule entries extend control to salts and isomers precisely so that a listed substance cannot be trivially modified into an unlisted one.
So each successive replacement was drawn from the same well that was already being watched, and each one arrived with less runway than its predecessor because the regulatory machinery was already pointed in that direction. The brands that reformulated from 7-OH into pseudo in early 2026 had roughly six months of relief for what was, in many cases, a full artwork and production cycle.
The generalisable test
Before committing to any candidate ingredient, ask: does its parent chemistry have a scheduling history? If yes, you are building on a foundation regulators have already shown interest in, and the timeline is not yours to control. If no, the compound has to be evaluated on its own terms — a far slower and less predictable process for everyone, including the agencies.
What it did to the shelf
The practical effect is a category that has been progressively stripped of differentiation. Take away 7-OH, pseudo, and the MGM compounds and what remains on most shelves is mitragynine — the same alkaloid, in the same tablet and shot formats, from every brand, distinguished mainly by label design and price.
That is a difficult place to run a brand. It pushes competition toward price, it makes retailer relationships fragile, and it means the thing a customer is choosing between is packaging.
It also creates an obvious opening for anything that can differentiate without carrying the same structural risk. We wrote about that separately.
The state layer, which gets less attention than it should
Federal action gets the headlines. State law is where most brands actually encounter regulation.
Kratom consumer protection statutes now cover a substantial share of the market, typically imposing age restrictions, labelling requirements, and registration or permitting. Six states prohibit kratom sale outright. Several states scheduled 7-OH and related compounds through emergency rulemaking months before the federal notices — which meant a product could be lawful in one market and a felony-adjacent problem in the next.
Emergency rules are the specific hazard here. They move fast, they are frequently not reflected in secondary sources for weeks, and they do not wait for anyone's production cycle. If you sell across state lines, checking your states individually is not optional. Our state page is a starting point, not a substitute for that.
What we would expect next
We are an ingredient supplier with an obvious interest, so weigh this accordingly. But the pattern supports a few reasonably confident statements.
- Further mitragynine derivatives will not solve this. Anything drawn from that chemistry starts with the attention already pointed at it.
- State action will continue outpacing federal action. It is faster, and the mechanisms are already in place.
- Marketing conduct will keep being the trigger. Where enforcement has landed, it has landed on claims — pain, withdrawal, dependence, substitution for medication. That is the most avoidable risk in this category and brands keep taking it. We wrote a guide.
- Differentiation will come from outside the kratom leaf or it will not come at all.
Our position on that last point is not neutral — we supply a corydalis-derived alkaloid and we think it is the most durable option currently available. What we would say to anyone weighing it: apply the test above to our product as readily as to anyone else's, and ask us for the reasoning rather than the assurance. It is written down.